Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula

NCT ID: NCT03236207

Last Updated: 2019-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-06

Study Completion Date

2018-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cow Milk Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test infant formula

Test non-commercial extensively hydrolyzed infant formula with HMOs

Group Type EXPERIMENTAL

Test extensively hydrolyzed formula

Intervention Type OTHER

extensively hydrolyzed formula with HMOs

Control infant formula

Control non-commercial extensively hydrolyzed infant formula without HMOs

Group Type ACTIVE_COMPARATOR

Control extensively hydrolyzed formula

Intervention Type OTHER

extensively hydrolyzed formula without HMOs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test extensively hydrolyzed formula

extensively hydrolyzed formula with HMOs

Intervention Type OTHER

Control extensively hydrolyzed formula

extensively hydrolyzed formula without HMOs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Born at term (\>36 weeks gestation)
* 2 months to \<4 years of age at enrollment
* Documented CMA within 6 months prior to enrollment
* Otherwise healthy
* Having obtained his/her legal representative's informed consent

Exclusion Criteria

* Children consuming mother's milk at the time of inclusion and during the trial
* Any chromosomal or major congenital anomalies
* Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs okay))
* Immunodeficiency
* Anaphylaxis to any food
* Receiving free amino acid formula
* Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol
* Currently participating in another clinical trial
Minimum Eligible Age

2 Months

Maximum Eligible Age

4 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Nowak-Wegrzyn, MD

Role: PRINCIPAL_INVESTIGATOR

Mt Sinai

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hoag Medical Group

Huntington Beach, California, United States

Site Status

Stanford University

Mountain View, California, United States

Site Status

Clinical Research Institute

Plymouth, Minnesota, United States

Site Status

Midwest Clinical Research

St Louis, Missouri, United States

Site Status

Breathe America

Albuquerque, New Mexico, United States

Site Status

Northwell Health System

Great Neck, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Allergy, Asthma and Clinical Research Center

Oklahoma City, Oklahoma, United States

Site Status

Carolina ENT

Orangeburg, South Carolina, United States

Site Status

Memphis & Shelby County Pediatrics

Memphis, Tennessee, United States

Site Status

Houston Clinical Research Associates

Houston, Texas, United States

Site Status

Allergy Asthma Research Institute

Waco, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16.16.CLI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Allergic Diseases in Infants
NCT03489733 ACTIVE_NOT_RECRUITING NA
Hydrolysed Rice Formula Study
NCT06288503 RECRUITING NA